Moreover, new modeling approaches (e.g., pharmacokinetic/pharmacodynamic models [27,49]) regarding treatment efficacy could investigate recent findings such as the relation of intestinal microbiota to anti-TNF-α treatment outcome in IBD patients [71,72]. Here, TNF is linked to inflammatory bowel disease.